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7Preface
Prevention is better than cure. If medicine residues do not end up in waste water then 
they do not need to be removed. We thus investigated whether medicine users would 
be willing to cut their contribution to medicine residues in our water, and how this 
behavioural change would impact upon the waste water itself.
A previous project by Water Authority Groot Salland had shown that advanced 
techniques could be employed to remove medicine residues from waste water. The 
technical complexity and the corresponding investment costs for this solution were 
the motivation for considering an approach that focuses on the source of the problem, 
i.e. the person. The water board thus created a cooperative partnership with Deventer 
Hospital. The fact that the hospital wanted to substantiate their goals with respect to 
sustainability meant that this approach was a logical step for them too. 
This required both organisations to cooperate on the boundaries of our core tasks. 
With support from Wageningen UR, the social study was set up and executed in the 
Radiology department in Deventer Hospital. 
We are both very enthusiastic about the results and the collaboration. Mutual 
appreciation has been expressed regarding the positive attitude, flexibility and 
commitment that were clear throughout the project. In line with this, we would also like 
to thank the patients, research staff and other relevant members of staff in Deventer 
Hospital and Water Authority Groot Salland for their efforts. Thanks to them, we can 
look back on a successful collaboration and some great research results. We would like 
to invite you to read this report on how we approached the research, the results and 
conclusions, what we have learned as a result and how we now wish to proceed. This 
project is a first step in a sustainable future with even cleaner water. 
We hope you enjoy reading our report.
On behalf of Deventer Hospital,               On behalf of Water Authority Groot Salland,
Jeroen Kleinjan (Board of Directors) Jan Oggel (Executive Committee)
Preface
8Summary 
Medicine usage in the Netherlands rose by almost 3% in 2014 and will continue to 
increase in the coming years due to the ageing population. Medicines end up in the 
sewerage system and surface water via urine and faeces. The current waste water 
treatment plants are inadequate in terms of removing this type of micropollutant. 
The impact of this form of micropollutant on the ecological water quality and the 
mixtures that are formed with other substances in the water are currently unknown. 
Nevertheless, the measured concentrations and effects that have so far been 
identified are ringing alarm bells in the Netherlands and the rest of Europe. The 
Dutch government is arguing for a strategy across the entire medication chain. The 
problem with medicine residues in surface water is not just a problem for the water 
managers and must be tackled chain-wide. The European Commission is expected to 
have drafted a strategic approach by 2016 and a package of measures two years later. 
Within Europe, various studies are taking place in order to provide building blocks 
for this strategic approach and policy development. The results of the ' Getting a grip 
on drug residues in our waters' project that are elaborated in this report, could also 
provide an important contribution. 
Research set up
In the project 'Getting a grip on drug residues in our waters', the focus lies on the 
beginning of the medicine chain. The aim was to investigate the extent to which 
patients are willing to contribute towards reducing medicine residues in water. The 
structure chosen was a study whereby CT-scan patients were asked to change their 
toilet behaviour. These patients were administered x-ray contrast agent prior to their 
scan. In ordinary circumstances, that would have been excreted via urine within 24 
hours and would thus end up in the surface water. The patients were approached by 
a research assistant after their scan, however, and asked if they would collect their 
urine in urine bags for 24 hours. The patients could dispose of these bags with their 
'grey' household waste and they would then be incinerated by the waste processing 
company. Measurements took place at the waste water treatment plant in Deventer to 
measure the effect of the study on the quantities of x-ray contrast agent in the waste 
water.
Results
During the research period, 1,224 patients were asked to complete a questionnaire. 
68% of them returned it. Of these respondents, 85% said that they had used one or more 
urine bags. Respondents were overwhelmingly positive with respect to experiences 
with the urine bag and their intention to use the urine bag in the future. The project 
partners were pleasantly surprised by these findings. Important success factors in the 
research structure include the personal approach to patients by research assistants, 
Summary
9the fact that the research was carried out in a hospital setting and the fact that the 
period covered was just 24 hours. Simultaneously, theoretical calculations suggest 
that the load at WWTP Deventer in the trial period reduced by one quarter. As a result 
of complicated factors, that came to light during the trial period, it was not possible to 
support the calculations with impact measurements and a full mass balance.
Recommendations
The findings from this study lead to recommendations for both the care and water 
sectors. These recommendations are:
• Hospitals that are working or wish to work with the 'Milieuthermometer 
Zorg' (Healthcare Environmental Thermometer) can include the findings in 
improvements for the environmental aspect 'waste water'. 
• Water managers are advised, with respect to similar measurement studies, to 
investigate whether a full mass balance can be set up prior to the study.
• Water managers and hospitals should work together in subsequent studies into 
the practicality of urine bags, in order to reduce medicine residues in water.
Summary
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Glossary
Flow
The flow is the average quantity of water that passes a specific point per time unit, 
expressed in cubic metres per second (m3/s).
Influent 
Waste water that is supplied for processing at a waste water treatment plant. This 
waste water comes from households, businesses and also from rainwater and is 
supplied to the purification installation via the sewers. After purification the water is 
referred to as effluent.
Iodixanol
Iodixanol is an x-ray contrast agent that contains iodine; it is given to the patient so 
that specific parts of the body are visible on an x-ray or scan.
Micropollutant
Pollution that is of a limited quantity but is undesirable due to its hazardous properties. 
It is a collective name for a large group of substances with various applications and 
diverse chemical characteristics. It concerns, for example, medication, hormones, 
softeners, fire-retardants, pesticides, UV filters and microplastics
Non-respondents
Persons who do not respond to a survey. 
Baseline situation
In scenario studies, this refers to the current situation, i.e. the situation without 
further interventions. It is also called a zero/baseline measurement, to which later 
measurements can be related. 
Polyclinic patients
Polyclinic patients are out-patients who may go home after a treatment or intervention 
and are not, therefore, admitted to hospital.
Respondents
Persons who do respond to a written survey.
Glossary
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Waste water treatment plant
In a waste water treatment plant (WWTP), the waste water from sewers is treated 
before it ends up in the surface water. The incoming dirty water (see influent) is 
treatedvia a number of processes that take place in the installation. One after the 
other, contaminants are removed via a grille or separation well to remove large 
particles, then settlement tanks to remove smaller particles and finally the soluble 
substances are removed using specific bacteria.
WWTP 
See waste water treatment plant.
Load
The quantity of a substance in grams.
Glossary
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1 Introduction 
1.1 Background and context 
1.1.1 Increasing medicine usage
Medicines have been developed so that they can have an effect on man and 
animals at relatively low concentrations. In the Netherlands, at the moment, 
there are almost 22,000 trading permits for human medicines, involving around 
1,000 different active substances (B. Klijn, personal communication, 10 October 
2014; Nefarma, 2013; RIWA/RIZA 2001). Of these active substances, using 
the available measurement methods, around 200 have been identified in the 
environment1, some of which are regularly found in the water chain (Derksen and 
Ter Laak, 2013). Medicine usage has risen substantially over the past few years 
and is expected to keep on increasing. This is primarily due to the fact that the 
population is ageing. Between 1 January 2014 and 1 January 2015, the number of 
people aged over 65 rose by 3% and medicine usage rose by 2.9%. According to 
population forecasts by the CBS, the ageing process will reach a climax in 2040, 
with the share of people aged over 65 reaching 26.4% The impact of this is clear 
from the pharmacies. Public pharmacies hand out three times as many medicines 
to those over 65 as they do to the average Dutch person, usually for chronic 
disorders (SFK, 2015).
1.1.2 Medicine residues in water
Once they have taken effect, medicines must then be excreted. Excretion via the 
urine (± 80%) and/or faeces (± 20%) leads to the original medicine, together with 
the corresponding metabolites, and via residential sewers, ending up in waste 
water treatment plants (referred to hereafter as: WWTP’s) (Derksen and Ter 
Laak, 2013). Despite the fact that the current WWTP's are not set up to remove 
micropollutants such as medicines, this does occur to a lesser or greater extent 
(metformin ± 90% and carbamazepine ± 9% - average 65%2). It all depends on the 
physical-chemical properties of the medicine and the specifications of the water 
treatment (STOWA 2011a). The rest of the medicine residues are discharged into 
surface water via effluent. Surface water concentrations of medicine residues 
usually lie between a few nanograms and a few micrograms per litre. In general 
the highest concentrations are found in smaller waters and in waters with a 
high level of WWTP-effluent (Grontmij, 2008; STOWA, 2011b; Derksen and Ter 
Laak, 2013; Laak et al., 2013; BIO Intelligence Service, 2013). Legal frameworks 
are lacking and there is currently (still) no policy for tackling this form of micro-
contamination. A few medicines have been placed on the so-called European 
Watchlist and, for this reason, are being widely monitored (European parliament, 
2013). 
1 Introduction
1 Newer measurement methods can now measure >1,000 substances (Wode et al., 2015)
2 This 65% removal rate is based on measurements at eight treatment plants for 27 medicines that are detected above the 
reporting limit (STOWA, 2011a)
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In some cases, it has been shown that medicines in very low concentrations have a 
detrimental impact on water organisms in surface water. In addition, water organisms 
are continuously exposed, over their lifetimes, to a mixture of multiple (decomposition 
products) medicines (and other substances) (Derksen and Ter Laak, 2013). Consideration 
must also be made of the possible accumulation in organisms, mixture toxicity and the 
creation of (active) decomposition products (STOWA, 2014). Man is also exposed to 
medicine residues that can be regularly detected in our drinking water, despite the 
advanced purification techniques that drinking water companies use to turn their 
sources (sometimes surface water) into drinking water. The concentrations of individual 
medicines in Dutch drinking water are so low (a few ng/L) that health risks are very unlikely 
(Schriks et al., 2010; Derksen and Ter Laak, 2013; Houtman et al., 2014). Given the effects 
of continuous exposure to (mixtures of) low concentrations of medicine residues are 
unknown, however, the possible risks must not dismissed out of hand. The perception 
of the user must also be considered: we don't want substances like that in our water. 
1.1.3 Central government and the EU - forming a vision
The fact that medicine residues have been shown in Dutch waterways since the end 
of the 1990's was the provocation for the Health Council3 (Gezondheidsraad) to issue 
a recommendation which asks for attention to be paid to the presence and risks of 
medicine residues in water (Gezondheidsraad, 2001) A working group '(animal) medicines 
in the environment' was then created, various exploratory (monitoring) studies took 
place and this topic was discussed at length in the House of Representatives (House 
of Representatives, 2007; House of Representatives, 2009; House of Representatives, 
2012; House of Representatives, 2013; House of Representatives, 2014a&b&c; House of 
Representatives, 2015a&b). Annex 1 provides comprehensive descriptions of the policy 
developments (European and national) over the past few years. The government is now 
applying a chain-approach whereby a source-based method at the beginning of the 
medicine chain (see §1.1.4) is encouraged, supplemented with measures at the end of 
the chain. Former Secretary of State Mansveld has taken steps to stimulate a source-
focussed approach among hospitals, pharmacies, the pharmaceutical industry and the 
water sector (House of Representatives, 2014b&c). 
Given the ambitions and complexity of the water quality policy, Minister Schultz van 
Haegen requested advice on this topic from the Dutch Water Advice Committee (AcW) in 
2015. According to the AcW, it is necessary to first create agreement between all parties 
about the degree of urgency and collectively recognise the problems (AcW, 2015). This 
requires a national approach with greater direction. The Minister, in a letter to the House 
of Representatives, then indicated that he would provide direction and that the definitive 
3 The Health Council has been an advisory body since 1902 and is tasked with 'providing information on the scientific situation 
with respect to issues relating to public health' to the government and parliament(art. 21 Health Act) (Health Council, 2001)
1 Introduction
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advice from the AcW (end 2015) would be used to further substantiate and execute the 
water quality policy (House of Representatives, 2015b) 
An interdepartmental working group, set up by and under the directorship of the Ministry 
of Infrastructure and Environment (I&M) is currently working on the development of an 
action plan for medicine residues in the chain. This is expected to be presented to the 
Minister at the beginning of 2016 (C. Blom, personal communication, 17 August 2015).
The above developments connect into the coverage that this topic has had at a European 
level in the context of the Water framework directive. This directive has been in force since 
the end of 2000, with the aim that good chemical and ecological surface water quality will 
be achieved by 2027 (European Parliament, 2000). The latest amended directive (Directive 
2013/39/EU), also states that the European Commission will deliver a strategic approach 
for medicine contamination in water by September 2015 (has been delayed; dated October 
2015 and not yet issued). In addition, the European Commission, in the context of this 
strategic approach and if appropriate, must draw up a proposal for a package of measures 
in 2017 (European Parliament, 2013).
1.1.4 A chain problem
Medicines can be a threat to aquatic life. This is a chain-wide problem, not only one 
for the water managers. That is why every chain player must make a contribution to 
the solution to this collective problem. The National Institute for Public Health and the 
Environment (RIVM) has set out the points at which the medicines are getting into the 
environment (figure 1). These are also the points at which measures could be taken. In 
annex 2, these intervention points (A to O) and the corresponding possible measures 
have been further detailed (RIVM, 2015).
There are currently many studies going on into the various solution areas for the 
different components of the chain. The pharmaceutical industry is principally 
focussing on points A and E. The EFPIA (European umbrella organisation for innovative 
pharmaceutical industry) has developed an Eco Pharmaco Stewardship (EPS), a 
platform for discussions about medicine residues in the environment (Ministry of 
Infrastructure and the Environment, 2015) An important element of this EPS is the 
proposal to monitor the environmental impact of medicine residues over a longer 
period. Some of the information about the environmental impact will also be improved. 
The EFPIA has also announced a publicity campaign with the title 'Don't flush drugs', 
whereby consumers will be encouraged to dispose of medicines they do not need 
responsibly instead of putting them down the drain or toilet. 
The healthcare sector is focussing on point D. The Ministry of Health, Welfare and Sport 
(VWS) started the programming 'Waste in Healthcare' in 2013. Within this programme, 
around fourteen organisations are working on a range of activities. These are focussed 
1 Introduction
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on topics such as unnecessary left-over medicines, the re-issuing of medicines and 
treatment tailored to and with the patient (House of Representatives, 2015a).
The UMC Utrecht and University of Utrecht are also working on the options for 
environmental labelling of medicines. This would allow medicines with a similar effect 
but a different environmental impact to be given a different label. This targets point C 
in the chain. In Sweden, there is a similar environmental classification system (SECIS4). 
Several hospitals, water boards and drinking water companies are also focussing 
on measures in relation to points I and O. This concerns the (decentralised) 
purification of medicine residues from water (UvW and Vewin, 2014). One of the 
examples of decentralised purification is the Pharmafilter concept that has already 
been implemented in the Reinier de Graaf Hospital in Delft and will soon also be 
introduced to a hospital in Terneuzen and two in Rotterdam (Pharmafilter, 2012). This 
is an integrated concept for improving healthcare and waste processing in hospitals, 
nursing homes and other healthcare centres. In this context, these institutions have a 
local waste water purification plant. This water purification system removes medicine 
residues from water. 
Another example of decentralised purification is the trial installation in the Antonius 
Hospital in Sneek. A five-year pilot has been running here since spring 2014; this 
enables techniques to be tested for purifying waste water from the hospitals. Prior to 
4 Swedish Environmental Classification and Information System for pharmaceuticals – www.fass.se  (currently only available in 
Swedish)
Figure 1:
Medicine chain. How do medicines end up 
in the environment? (RIVM, 2015). 
A. Development and production; 
B. Access to the market; 
C. Purchasing and sales by pharmacies; 
D. Prescription and use; 
E. Disposal with household waste; 
F. Disposal via sewerage system; 
G. Collection of unused medicines; 
H. Collection of household waste; 
I. Treatment of sewerage water; 
J. Dump for household waste; 
K. Incineration of household waste and sludge; 
L. Sewage sludge used in agriculture (not in NL); 
M. Treated waste water is discharged into surface water; 
N. Small chemical waste is incinerated; 
O. Drinking water companies supply water.
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this, Water Authority Groot Salland carried out the European PILLS5  project between 
2008 and 2012, in collaboration with bodies such as the Isala klinieken (hospital in 
Zwolle, The Netherlands) and Vitens. A compact and innovative waste water purification 
system has been built at the water board site to specifically focus on more effecitvely 
removing medicine residues from the waste water from the neighbouring Isala clinics. 
Other European initiatives such as TAPES6, DEMEAU7 and SOLUTIONS8  focus on 
technical measures and the design of instruments to support decision-making. 
A European initiative that has focussed on the user/patient (D - after administration 
- to F) is the follow-up to PILLS, called noPILLS. This European project concentrates 
on source reduction and awareness. Project partners were two German water 
boards, universities from Limoges (France) and Glasgow (Scotland), a scientific and 
technological research body from Luxembourg and the Dutch RIVM. In the period 
between 2012 and 2015, public campaigns (D-E) were carried out in France, Germany 
and Scotland to increase societal awareness of the consumption and removal of 
medicines (noPILLS, 2015). It was thus concluded that the ordinary citizen as patient 
and employees from the care sector are receptive to the idea of helping to reduce the 
impact of medicine residues on the environment. Everyone has a clear opinion on the 
(over) consumption of medicines and they would like clear, accessible and consistent 
information about correct usage and disposal. There is also a willingness among the 
public at large to 'do the right thing'. 
noPILLS also carried out a two-week urine separation campaign with urine bags (F) 
in two hospitals (Germany and Luxembourg). The conclusion is that it is possible to 
introduce procedures for separated urine into radiology departments (requires five to 
ten minutes extra per patient) and that the active involvement of the medical personnel 
is the key for efficiency. There is also a clear need for information for medical personnel 
regarding the impact of medicine residues on the environment.
The most effective approach to medicine residues in our water is expected to be a 
combination of measures at the beginning and end of the chain, or management 
across the entire chain (see figure 1). Local and regional studies can make a significant 
contribution towards the development of this all-in approach. Research can further 
develop expertise in this area, provide insights into which measures can be taken and 
where and also how effective they are. As a result, possible relevant building blocks 
will be created for the development of an integrated approach with measures focused 
on both the beginning and end of the chain. The project 'Getting a grip on drug 
residues' provides a building block via an intervention in the chain by the medicine 
user themselves (F). The options and bottlenecks with regard to an approach at the 
end of the chain are thus explored.
1 Introduction
5 Pharmaceutical Inputs and eLimination from Local Sources. European project in which the removal of medicine residues 
from waste water was the central point, focussing on so-called ‘end-of-pipe measures’.
6 Transnational Action Program on Emerging Substances - http://www.tapes-interreg.eu/ 
7 Demonstration of promising technologies to address emerging pollutants in water and waste water - http://demeau-fp7.eu/ 
8 Solutions for present and future emerging pollutants in land and water resources management
 http://www.solutions-project.eu/ 
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1.2 Provocation and problem outline
The direct provocation for 'Getting a grip on drug residues in our waters' was the 
PILLS project outlined above. The technical complexity and the necessary investment 
costs linked to the separate purification of hospital water were the provocation for 
considering an approach that focuses on the source of the problem, i.e. the person. 
Water Authority Groot Salland thus explored the options for cooperation with Deventer 
Hospital. This hospital is very enthusiastic about the source approach and would like 
to actively substantiate its social role in this context. The project is not part of the 
European noPILLS project but does connect into the corresponding goals and method. 
If it transpires that the approach of the underlying research is successful, these results 
could also contribute towards the reduction of emissions of other micropollutants 
into surface water.
1.3 Reading guide
The research structure will be elaborated in chapter 2. In §2.1, the main questions will 
be formulated and the corresponding objective and hypothesis will be set out. §2.2 
will cover delineation, detailing which choices were made and how this came about. 
Finally, §2.3 explains the ultimate working method which was actually used prior to 
and during the research period.
Chapter 3 presents the results. This chapter comprises two sections: the results of the 
study of CT patients in Deventer Hospital and the result of the study into the impact on 
waste water quality by WWTP Deventer. 
Chapter 4 concludes the results as set out in chapter 3, sets out learning points from 
this research and makes connections to the future; where do we go from here? This 
chapter provides the plans for the two cooperative partnerships in this project and 
outlines the recommendations for hospitals and water managers regarding how this 
research could be significant to them. A number of possible follow-up studies are also 
elaborated. 
The annexes contain supplementary information about policy development regarding 
water quality in the Netherlands and Europe (annex 1), possible action points 
for measures in the medicine chain according to the RIVM (annex 2), the working 
instruction for Deventer Hospital research assistants (annex 3), information about the 
Chronbach’s alpha test used to analyse results (annex 4) and a map of the sewerage 
systems in Deventer (annex 5).
1 Introduction
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2 Research 
2.1 Goal 
The project ‘Getting a grip on drug residues in our waters' studies the following central 
question: 
Are patients prepared to make a contribution to prevent or reduce medicine residues 
in waste water? 
The aim is to investigate where an intervention can be made in the chain and if end-
of-pipe measures transpire to be insufficient or are limited in terms of resolving the 
problem of medicine residues in waste water. Research also covered the extent to 
which the impact of this intervention can be measured in the waste water (influent). 
For the purposes of the central questions, a decision was made to approach polyclinic 
patients who were to undergo a CT scan in Deventer Hospital and were therefore given 
x-ray contrast agent. They were asked to collect their urine in a urine bag for a period 
of 24 hours and then dispose of them with the 'grey' waste for incineration. Little is 
known about the environmental load that corresponds to this process but, as a result 
of conversations with environmental and waste processing experts, it is estimated 
that this waste route is less environmentally damaging than draining x-ray contrast 
agent into surface water. The hypothesis is that the research will result in an effective 
method for behavioural change and awareness-raising. We also hope, on the basis of 
results, to be able to make a statement on the scalability of this method(s) to other 
substance groups and/or medicine users, e.g. cytostatic drugs (for cancer prevention) 
or chronic medicine users, such as those with diabetes. 
During the study, the focus lay on this social aspect. Wageningen UR provided 
sociological expertise and support with respect to the structure and working method 
of the research. The study's secondary aim was to measure the effect of intervention 
in waste water.
2.2 Research set-up and delineation
The method of approaching patients within a hospital was chosen because it is 
relatively easy to control the environment compared to approaching medicine users 
in residential areas. Despite the fact that the highest loading of medicines comes 
from residential areas (Le Corre et al., 2012: Hermann et al., 2015), the distribution 
of medicine users is greater there and it would be more difficult to approach them. 
With a small-scale study on an individual level, the success factor of the hospital-based 
approach is greater.
2 Research
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2.2.1 X-ray contrast agent as medicine group
In the study, x-ray contrast agent was used as the medicine group due to the high 
loads and concentrations observed in the water environment. Although this group 
of substances is less relevant in terms of toxicity compared to medicines such as 
cytostatic drugs, the load of x-ray contrast agents that end up in the WWTP every year 
is as high as all other medicines put together (Grontmij, 2011). 
The patients who were asked to participate in the study are polyclinic patients at 
Deventer Hospital who had been given the x-ray contrast agent iodixanol prior to a 
CT scan. The contrast agent iodixanol is the most frequently used agent for CT scans 
at Deventer Hospital. The agent is also primarily excreted via urine (97% within 24 
hours), meaning that it can be almost entirely collected in the urine bags. The 
maximum concentration in the urine is reached within one hour. Clinical patients are 
not approached as these patients are generally bed-bound and need assistance to go 
to the toilet. As a result, the willingness of the patient is not being tested and the load 
is placed on the hospital staff.
2.2.2 Urine bags as aids
A urine bag was selected for urine collection (figure 2). It is available in both male and 
female versions. The urine bag contains gel beads that absorb urine so that it does not 
leak out. The bags can be disposed of with household waste and then incinerated by 
the waste processing company with the rest of the waste. These urine bag have also 
been used in similar research that was carried out as part of noPILLS (see §1.1.4 and 
§1.2). Other methods to keep medicine residues out of the water system are also under 
development. This concerns, for example, mobile toilets for the home for cytostatic 
drug users (Pharmafilter, 2012) and toilet blocks or toilet paper containing active 
carbon which absorbs the medicine residues (adhesion). Urine bags were chosen for 
the project because they are suitable for the patient and do not correspond to any 
risks.
2 Research
Figure 2:
Urine bags used for this study 
A. Male version
B. Female version 
A
B
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In order to research whether the use of urine bags impacted upon the quality of 
waste water, the incoming waste water (influent) at the RZWI Deventer was measured. 
Deventer Hospital is the most relevant source of iodixanol in the WWTP Deventer's 
sewerage area. Iodixanol is also used in a nearby radiotherapy centre. These quantities, 
however, are negligible (± 5%). It is also possible that patients who have been given 
iodixanol by another hospital have used the toilet within this sewerage system. This 
percentage is unknown but is also regarded as negligible. 
A decision was made to run measurements alongside the regular sampling programme. 
This involves an alternating pattern, only on weekdays. A condition was that the 
postcodes of the polyclinic patients and the details of the iodixanol administered 
within Deventer Hospital were known during the trial period. These details were used 
to investigate whether a mass balance could be used to ascertain whether the use of 
urine bags had impacted upon the concentration of iodixanol in the incoming waste 
water at WWTP Deventer.
The study did not concentrate on the objectives outside the water authority’s direct 
sphere of influence, such as reducing medicine consumption or influencing the 
production of medicine. Neither did this project focus on the development of end-of-
pipe technology by the water authority, as was the focus in the PILLS project.
2.3 Working method
On 12 December 2014 a pilot study of eighteen CT scan patients was carried out to 
check whether the selected approach method (request for cooperation, time, place 
and method of address by research assistant9, instruction for patients via written 
or audio-visual material) was feasible in practice. The response-friendliness of the 
questionnaire was also examined during the pilot. At the location, the participant 
completed a short questionnaire asking about gender, age, postcode, if any assistance 
is required to pass urine and contact details for a telephone call if there are unclear or 
missing details. The patients were then given a long questionnaire to take home and 
complete and then send back in the envelope provided, in order to find out:
• whether and how many urine bags had been used;
• the experiences of the patient with the urine bags;
• whether the willingness to use the urine bags corresponded to environmental 
concerns;
• how the patients felt about the approach used by the study; 
• how patients felt about the issue of medicine residues in our water; 
Patients who had chosen not to use the urine bags were also asked to complete 
the questionnaire. This was to demonstrate why patients had not been willing to 
2. Research
9 Specially selected and trained volunteers from Deventer Hospital.
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participate. The analysis of the answers on the questionnaire form the most important 
element of the results. 
On the basis of this pilot, the questionnaires were modified and the materials (use of 
urine bag) were chosen. The protocol for the research assistants was also drawn up 
(see annex 3) so that all patients would receive the same personalised approach. A 
personal approach to patients was selected because this was expected to produce a 
better response than simply handing out or sending a questionnaire. In addition, the 
topic (urinating) and the setting (the hospital, in which the results of a CT scan could 
drastically change somebody's life) lent themselves to the personal approach. 
Data collection began on 26 January 2015, in Deventer Hospital. Polyclinic patients 
(see §2.2) who underwent a CT scan with the contrast agent iodixanol were informed 
by the CT technician that they would be approached in the waiting room by a research 
assistant regarding an ongoing study. Patients that have had a CT scan usually spend a 
little time in the waiting room afterwards due to possible side-effects from the contrast 
agent.
After the scan, the patients were approached by research assistants from the hospital 
with three requests:
1. completing a short questionnaire;
2. using a urine bag for 24 hours after the examination;
3. completing a longer questionnaire (regardless of whether they had used the urine 
bags). 
The short questionnaire was completed in the waiting room and handed back to the 
research assistant. Patients were also given a bag containing information on the study, 
seven urine bags, the long questionnaire, a bottle of antibacterial hand gel, a ticket for 
a cup of coffee in the hospital restaurant and also a booklet for children on the subject 
of medicines in our water.
In the waiting room, from 13 February 2015, an animation10 about medicine residues in 
waterways was played on the television. This short film was interchanged with a series 
of films about the hospital and CT/MRI scans. The number of patients who actually saw 
this animation is unknown11. 
Patients who had not returned the long questionnaire a week after their CT scan and for 
whom a telephone number had been noted (from the short questionnaire) were called 
by a research assistant from the hospital. The protocol for this telephone component 
was to ask if they had used the urine bags (if so, how many; if not, why not), whether 
they were going to send the questionnaire back (if not, why not) and their response to 
the statement: 'Medicine users are asked to use urine bags too frequently'.
2. Research
10 http://www.wgs.nl/schoon-water/grip-medicijnresten-0/achtergrond/grip-medicijnresten/ 
11 As a result of the setting of the waiting room (it was unclear which patients had seen the film or could see the film) and the 
limited space on the questionnaire, it was impossible to measure the impact of the film on the willingness to use urine bags.
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In order to ascertain the extent to which behavioural change could be measured in 
the water, measurements were taken in the incoming waste water at WWTP Deventer. 
Samples were taken from this waste water (influent) for 24 hours; they were then 
analysed by the Aqualysis laboratory for the level of iodixanol. With the registered 
supply flow, the supplied loading in grams per day was calculated. For organisational 
and technical reasons, the influent quality was not sampled every day. A alternating 
pattern is followed which covers all working days at around the same ratio. In order to 
create a comprehensive mass balance, it was therefore important to be able to make 
reliable assumptions regarding influent quality on the days when no measurements 
were taken.
2. Research
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3. Results 
In this chapter the results are presented for both the research in Deventer Hospital 
among polyclinic CT patients (§3.1), and the effect measurements at WWTP Deventer 
(§3.2). The significance of this research for a source-focussed approach to medicine 
residues in waste water is further elaborated in chapter 4. 
3.1 Are patients willing to do their part?
A CT scan that used iodixanol was carried out, on average, on around ten to fifteen 
polyclinic patients per day. On other days during 
the week, PET scans were also done using 
iodixanol. The frequency of these and numbers 
of patients varied per week. Research assistants 
were given an overview each day of all of the 
patients that were eligible for the research. For 
practical/organisational reasons (availability of 
research assistants, scans that were carried out 
simultaneously in different rooms), it was not 
possible to approach all patients for the study. 
In addition, some of the patients attended in 
the evening or at the weekend to be treated 
urgently and there were some who did not want 
to participate right from the start. 
A total of 1,224 patients completed the short 
questionnaire. 831 patients filled out the long 
questionnaire as well as the short questionnaire 
(referred to hereafter as 'respondents'). This 
total figure includes the 193 patients that only sent the questionnaire back once they 
had been called by a research assistant from the hospital. This subsequent telephone 
contact turned out to be very effective: 47% (193 of the 41112  patients who were 
contacted by phone) then returned the long questionnaire. 
Not all respondents completed all of the questions. The results are based on the 
answers given. Missing answers were omitted per answer. Of the 831 people who 
completed the long questionnaire, 56% were male and 44% female. The age division 
among respondents is shown in figure 3.
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3.1.1 Use of urine bags and experiences
Reported use
Of the 831 respondents that completed the long questionnaire, 708 respondents (85%) 
indicated that they had used one or more bags. During the subsequent telephone call 
follow-up, it was found that 105 patients who had sent the questionnaire back had 
used one or more urine bags.
Of all of the respondents, 99% indicated that 
they had not needed any assistance when 
using the urine bags. Of the 24 respondents 
that indicated in the short questionnaire that 
they needed assistance in order to pass water, 
seven also completed the long questionnaire. 
Of these seven respondents, three (two male 
and one female, between the ages of 65-80) 
indicated that they had not been able to use 
the urine bag without assistance. In addition, 
seven respondents (five male and two female 
aged between 40 and 80+) who had indicated 
that they had not needed assistance to pass 
water, said that they had required assistance 
to use the urine bag.
Of the 708 respondents that had used the 
urine bags, 35% used all seven urine bags 
(figure 4). 49% used four to six urine bags and 
16% used up to three urine bags. 87% of the 
males and 84% of the females used one or 
more urine bags. 3% of the males and 12% of the females used one urine bag and 30% 
of the males and 41% of the females used all seven urine bags.
In total 14% of the respondents did not use the urine bags. Of these 33% were under 
the age of 24, 17% fall into the age range 25-40, 10% were between 41 and 64 years 
old, 14% are between the age of 65 and 80 years and 21% were older than 80.
In the questionnaire, respondents were able to provide several answers as to why they 
used no or less than seven urine bags. 63% of the respondents indicated that they 
used no or less than seven urine bags because they didn't need them in the 24 hours 
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after the scan. 20% of the respondents used less than seven urine bags because they 
found it too inconvenient (figure 5a).
Other reasons the respondents gave were: forgot (6%), found it unhygienic (6%); did 
not know where to put them (2%); had a catheter (2%). 98% of the respondents used 
and disposed of the urine bags at home. Of these respondents 23% used the bags at 
multiple locations and 20% disposed of them at different locations (figures 5b&c).
Experience with the use of urine bags
Of the respondents, 91% of the respondents like the format and 94% liked the opening 
of the urine bag (figures 6a and 6b). 69% of the respondents found the instructions to 
be clear and 24% of the respondents found the instructions to be 'neutral' (figure 6c). 
The answer categories for this last question deviate from the other two questions in 
terms of experiences with the use of the urine bag. This could explain the difference 
between the over 90% of the respondents who found the format and opening or 
the urine bag to be satisfactory and the 'just' 69% of the respondents who found the 
instructions to be clear.
Opinions on the use of urine bags
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Almost 90% of the respondents agreed with the statement 'I found it easy to urinate 
using the urine bag'. In addition, 90% of the respondents  found the urine bag easy 
to dispose of. 100% of females and 31% of males found urinating in a urine bag less 
hygienic than urinating in the toilet. 9% of the respondents indicated that their current 
health situation had made it difficult to use the urine bag. Relatively more of those 
aged over 80 indicated that their current health situation had made it difficult to use 
the urine bag. Around half of the respondents agreed with the statement that they 
would rather nobody knew about them using a urine bag.  Graph 1 visualises the 
statement about use of the urine bag.
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Graph 1: Opinions on the use of urine bags
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3.1.2 Intention to use urine bag or not
Future use
When it comes to future use, 44% of the respondents indicated that they would use 
the urine bag if there was no nearby toilet; 48% if the doctor prescribed them and 55% 
to contribute towards a better environment. 37% of the respondents ticked multiple 
answers for this question. The opinions of males and females did not vary significantly 
with respect to future use of the urine bag. Contrary to the norm in attitude research, 
this study asked about behavioural intentions among respondents that had already 
been made aware of and had gained experience with the desired behavioural change 
(i.e. use of urine bag). 
To statements regarding the intention to use the urine bag (graph 2a), the most 
positive response was given to the question of whether respondents, as patients, 
wanted to contribute towards solutions to the problem of medicine residues in our 
water (86% agreed). Just 3% of the respondents disagreed with this statement. The two 
other statements that relate to the environment score relatively positively. 75% of the 
respondents agreed with the statement 'Collecting urine in a urine bag instead of the 
urine ending up in the sewerage system, and thus in the surface water, is better for the 
environment'. 64% of the respondents agreed with the statement 'Hospitals must hand 
out urine bags as standard in order to collect medicine residues'. Furthermore, 62% 
of the respondents indicated that medicine users were not asked to use urine bags 
overly frequently. 66% of the respondents agreed with the statement that patients 
should not be troubled about environmental issues as a result of their medicine usage. 
38% of the respondents agreed with the statement 'urine bags are unsuitable for user 
for longer than 24 hours', compared to 29% who agreed with this and 33% who had 
no opinion.
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Intention to use urine bags in relation to environment concepts
There was a check on whether the above environmental statements (graph 2b) are 
cohesive. In other words, whether they could form one scale due to sufficient internal 
consistency. This is not the case (see the Cronbach's alpha test, annex 4). This means 
that we are unable to collate the results of the environmental statement in order 
to seek correlations with, for example, age or gender, or with the answers to other 
questions and statements.
The following findings relate to the respondents that indicated they would use a urine 
bag in the future if this meant they would be contributing to a better environment (86% 
of the total). These findings are therefore not included in graphs 2a and 2b. A large 
majority of these (89%) stated that collecting the urine in a urine bag was better for 
the environment than the urine ending up in surface water. 81% of the same group of 
respondents agreed with the statement that urine bags should be issued as standard 
in order to collect medicine residues. Just 10% of these respondents thought that 
patients should not be troubled about environmental issues due to medicine usage. 
78% agreed with the statement and 12% had no opinion. Medicine users are not asked 
too frequently to use urine bags according to 80% of the respondents. When it comes 
to who should take measures in the medicine/water chain, 16% of the respondents 
believed that it was better to modify the waste water treatment plant than ask users 
to collect their urine. 70% agreed with the statement and 14% had no opinion. 41% of 
these respondents said that it was better to make medicines more environmentally-
friendly than ask patients to collect their urine. 37% agreed with the statement and 
22% had no opinion.
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3.2 Effect in waste water at WWTP Deventer
3.2.1 Theoretical effect
Figure 7 is a schematic representation of the routes taken by and quantities 
(percentage) of iodixanol from Deventer Hospital that end up at an WWTP. The 
diagram shows that around half of the quantities of iodixanol administered ultimately 
end up at WWTP Deventer. The rest ends up in another WWTP because almost two-
thirds of the patients treated in polyclinics live outside the sewerage catchment area 
of Deventer (see annex 5 for the map of Deventer's system).The extent to which the 
iodixanol occurs in Deventer's waste water can be ascertained on the basis of the 
questionnaires filled in. The following details are important in this context:
• The questionnaires show that 85% of the 831 respondents used one or more 
urine bags. 
• Of the non-respondents, around half did use urine bags (information from 
telephone follow-up). 
• About 40% of the polyclinic patients live within the area that is connected to the 
WWTP Deventer. 
• The Radiology department at Deventer Hospital recorded how much iodixanol 
was administered to each patient. 
• Just under 30% of the polyclinic patients were not approached to use urine bags 
(see §3.1). 
A calculation using the above figures shows that the total quantity of iodixanol that 
was used in the polyclinic's CT department was collected within the urine bags. The 
3. Results
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Figure 7: Loading and routes of iodixanol from Deventer Hospital to 
WWTP’s in normal situation
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clinical department is also responsible for some of the iodixanol that ends up at the 
WWTP Deventer. The clinical patients were not offered a urine bag (see §2.2.1). This 
equates to around a quarter of the total iodixanol that is administered via the hospital. 
Around 8% of the iodixanol is administered in other departments. These patients were 
also not offered urine bags.
The result is that a third of the total amount of iodixanol administered by Deventer 
Hospital, was collected. If we focus on the WWTP Deventer, the load on the WWTP 
during the trial period reduced by a quarter according to the modelled mass balance. 
This is further illustrated in figure 8.
3.2.2 Measured effect
During the research, checks were made on whether the quality improvements (§3.2.1) 
in the waste water, derived from modelling, were also clear in practice on the basis of 
measurements of the waste water at the WWTP Deventer. The quantities of iodixanol 
(loading) that is administered on a daily basis, after correction for the part that was 
collected in urine bags, was compared with the loading that ended up at the WWTP 
Deventer. The aim was to establish whether the use of urine bags was measurable, by 
creating a comprehensive mass balance. As a result of various factors, that became 
clear during the measurement period, it was not actually possible to demonstrate 
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the realised water quality improvement using the measurement method proposed in 
advance. The scope of the individual error sources and the sum thereof was difficult 
to quantify. We were unable to gain an insight into the largest of these error sources 
and it could not be quantified in advance. At a later stage of the research, it therefore 
transpired that the current measurement method was inadequate for measuring 
the effects of this intervention on waste water quality. The measurement research 
provided great insights that are briefly elaborated in chapter 412.
3. Results
12 Measurements and the combination of patient details, administration details and details about the quality and flow of waste 
water have been evaluated. This led to a number of recommendations that are not all covered by this report. These can be 
provided to anyone who is interested. You can contact Water Authority Groot Salland for this purpose.
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4. What has this study shown? 
4.1 Conclusions
4.1.1 Willingness to use urine bags among CT patients is high 
In general, the level of willingness to use urine bags among CT patients is high 
and this does not depend on age or gender. Respondents were overwhelmingly 
positive with respect to questions about their experiences with the urine bag and 
their intention to use the urine bag in the future. Respondents who used fewer 
than seven urine bags provided various reasons why they had not used all seven 
bags. This was generally due to practical reasons, such as not requiring the full 
seven bags, being outside the home, and unexpectedly having to go to the toilet, 
or having diarrhoea after the scan and not being able to use them. It is worth 
noting that most of the respondents did not stop using the bags because of the 
urine bags themselves. This applied to around 30% of the respondents, who found 
it less hygienic to urinate in the urine bag than in the toilet. By far most of the 
respondents found the design of the urine bag to be good, the instructions clear 
and they found urinating into the urine bag to be easy. Respondents largely used 
the urine bags at home and did not have any difficulty disposing of the full bags in 
the waste container.
A few indicated that they were only cooperating because it was a research project 
and that urinating into the toilet is more pleasant or hygienic. Other respondents 
indicated that they found the urine bags handy for use out of the home or if the 
toilet was not clean.
A result worth noting is that a relatively high number of males think the urine bags 
are unsuitable for females whereas females found them to be suitable. One reason 
for this could be that men are not familiar with the female version of the urine bag.
A (more) positive score from respondents regarding the statement about the 
environment did not impact upon the actual use of urine bags. This is even less 
relevant for experiences with the urine bags or the intention to use them in the 
future. One reason for this could be that the majority of the respondents score 
positively on the (future) use of urine bags and the experiences with them, 
anyway. Sub-groups cannot be distinguished because the response to all items 
is overwhelmingly positive. In other words, if greater diversity had been found 
in the answers to the statements, this diversity could have been correlated to 
the variables age, gender or others. Given that all of these categories of patient 
provided similar responses, it can be concluded that age category13 or gender has 
little impact on the willingness to use urine bags.
4. Conclusion
13 Younger patients (under the age of 40) are not really represented in this study. The conclusion applies to the age range above 
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4.1.2 Personal approach and hospital setting explain greater willingness to take part 
in study
A large majority of the CT patients were willing to contribute towards preventing 
medicines ending up in surface water by using urine bags. It is worth noting that a 
small majority of these people believe that medicines should be manufactured to be 
more environmentally-friendly rather than patients having to use urine bags. Just a 
minority believe that it would be better if the sewerage purification process could be 
adapted to resolve the problem rather than patients having to collect their urine. This 
gives an overview of how patients position themselves in the waste water chain when it 
comes to medicines in waste water. In the first instance, this is regarded as an issue for 
the pharmaceutical industry, then for the consumer and, finally, for the water boards. 
A possible additional explanation for the high and positive response is, firstly, 
the personal approach to patients by research assistants. This type of intensive 
approach can be expected to increase response levels. Patients that did not send the 
questionnaire back within one week were also called by one of the research assistants. 
This process was very effective (47% of the patients returned the questionnaire after 
they had received a call). 
The second possible explanation for the high response is the fact that the study took 
place in a (for most people, out-of-the-ordinary) hospital setting. If hospital staff 
distribute a medical survey in their own waiting room, the response is expected to 
be higher than for a survey that is sent out by post. In addition, the extraordinary 
situation of having to have a CT scan also equates to the patient being more accepting 
of other non-ordinary practices, such as urinating into a urine bag. 
A possible explanation for the high degree of willingness to use urine bags is that the 
effort required only covers a time-span of 24 hours.
4.1.3 In theory, load of iodixanol at WWTP Deventer decreased by a quarter during 
trial period
Calculations can be used to conclude that the iodixanol load at WWTP Deventer 
decreased by one quarter during the trial period. 
As a result of complicating factors, such as various missing details in the administration 
phase and drainage phase (toilet and urine bag usage), uncertainties in the transport 
phase (sewerage system) and margins of error in the measurement phase, it was 
impossible to support the calculations with impact measurements and a comprehensive 
mass balance. 
It would seem advisable, prior to the research, to carry out a baseline measurement 
4. Conclusion
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for a reasonable period in order to check whether a mass balance can be created. It 
can then be established whether measurements involving the influent quality are of 
added value.
4.2 Lessons learned
4.2.1 Good collaboration with Water Authority Groot Salland and Deventer Hospital
The collaboration between Water Authority Groot Salland and Deventer Hospital was 
new, as was the project. A similar project, as set out in chapter 1, had taken place 
within the European noPILLS project, but the results had not been published prior 
to the start of this study and the scope of noPILLS was limited (two-week approach).
The cooperation was found to be satisfactory by both sides. Both parties mentioned 
the other party's enthusiastic attitude, flexibility and hard work, as strong points. 
The parties listened to one another and sought solutions together. This provided 
new insights even within the individual organisations. Both parties also expressed 
appreciation for the enthusiastic, voluntary efforts made by the research assistants 
who had approached the patients. Their hard work was one of the most important 
success factors within this research. 
4.2.2 Better preparation for employees and project leader in Deventer Hospital
Several areas for improvement were noted with respect to the work-floor. First of 
all, this concerns improved preparation with regard to the approach method, and 
providing information to and preparing the research assistants. The impact of and 
information requirements of the CT laboratory assistants was also underestimated. 
They should have been involved and kept informed right from the start. The sociological 
expertise of Wageningen UR could have been put to better use in both contexts.
Areas for improvement according to both cooperative partners included having a 
project leader in the department in which the research was taking place (in our case, 
the Radiology department) and creating a more private area where patients could be 
approached, to provide a sense of privacy (the public CT/MRI waiting room was used).
4.2.3 Volunteer research assistant is most important key factor
What was most noteworthy from the social research was the high degree of 
accessibility, positive reactions and willingness of patients to cooperate. Prior to the 
study, this was estimated to be lower. There was only a small group that was not 
willing to meet the research assistant. A relatively high percentage of patients made 
the effort to complete the questionnaire and send it back; the majority of these were 
also willing to use the urine bags. The efforts of volunteer research assistants and the 
referrals to them by the CT laboratory assistants were a significant key factor in the 
study.
4. Conclusion
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4.2.4 Include more background variables in survey
The questionnaires could have been improved by including more background variables 
(example: see §4.3.3), so that sub-groups could be distinguished. The results could 
then have been related back to the research strategy for specific target groups. It also 
transpired that volunteers and lab assistants could sometimes unwittingly influence 
patients with their enthusiasm. Better instructions and guides provided in advance 
could have helped.
4.2.5 Setting up a mass balance prior to the research is vital
Within this project, a great deal of knowledge was gained regarding measuring the 
impact of an intervention in waste water. The most important learning point is that, 
prior to the trial period, it should be established whether a comprehensive mass balance 
can be created. If this is possible, the effect of an intervention can be quantified. This 
also requires a longer period of measurement of the waste water in advance of the 
intervention so that a representative baseline situation can be established against which 
the data from the trial period can be compared. In order to realise an effective mass 
balance, measurements must be taken continuously (seven days per week). This is 
due to the high fluctuations in administration quantities in combination with the large 
variations in travelling time of iodixanol to the WWTP. Other learning points relating to 
the use of measurements can be explained in person. 
Other uncertainties that impacted upon the creation of a mass balance, could possibly 
have been accommodated via modifications to the patient approach. This includes 
outlining the importance of the first (two) urination(s) being collected and/or a more 
concrete question about (the location of) the first urination being included in the survey. 
Ultimately, however, not all error sources are easy to identify and minimise. This refers, 
for example, to the (unknown) error in the debit flow measurement for one of the waste 
water pipes that discharge into the WWTP Deventer.
4.3 Next steps
4.3.1 Planning for project partners
The project at Deventer Hospital taught us that patients are aware of the environmental 
impact that corresponds with medication. Patients are genuinely willing to contribute to 
reducing this environmental load, despite their health problems. The project also raised 
awareness and willingness to cooperate among those providing care at the hospital. 
This realisation reinforces the belief that Deventer Hospital has a social task to help 
resolve environmental issues. The fact that urine bags are not suitable for every type of 
medicine, means that Deventer Hospital believes that additional research should focus 
on the medication itself. Research must take place, with the pharmaceutical industry, 
into how medication can be made less damaging to the environment. 
4. Conclusion
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As a result of this project, Water Authority Groot Salland is aware that it is possible 
to reduce specific medicine residues in waste water before the water flows into the 
WWTP. The project flagged up the importance of cooperating with parties that are in 
direct contact with the user of a problematic substance (in this case, medication). By 
taking collective responsibility, Water Authority Groot Salland and Deventer Hospital, 
enabled the discharge of this problematic substance to be reduced. A positive side-
effect of this project is that the collaboration with Deventer Hospital also raised 
awareness about the contamination of waste water with medicines within the hospital 
as a whole. The water board will include this fact in its efforts to realise its vision of 
being connected into its surroundings. 
Both Water Authority Groot Salland and Deventer Hospital were pleasantly surprised 
by the fact that a majority of CT patients were willing to contribute towards preventing 
medicine residues ending up in the water. This provides an impetus for further 
research. It is, for example, still unclear as to whether CT scan patients would be 
similarly willing to contribute if urine bags were part of the routine (and there was no 
personal approach by a research assistant) or if they were asked to use them for longer 
than a 24-hour period, and also whether the urine bag could be effective for other 
patients too. That is why both Water Authority Groot Salland and Deventer Hospital, in 
collaboration with other parties, would like to cooperate in the realisation of follow-up 
research in order to provide insights into these uncertainties.
4.3.2 Recommendations for the future
The research results are valuable for hospitals that would like certification with respect 
to sustainability via the Environmental Care Thermometer (Milieuthermometer Zorg) 
from the Environmental Care Platform (Vereniging Milieu Platform Zorg/MPZ) and 
Environmental Inspection Association (Stichting Milieukeur/SMK), the development of 
which was encouraged by Secretary of State Mansveld (see annex 1). The environmental 
aspect of 'waste water' encompasses requirements regarding the drainage of 
chemicals and medication into waste water. Preventing the contrast agents that are 
administered to patients ending up in the sewerage systems, is specifically mentioned 
in the certification programme.
 
In addition, the information from this research is valuable for water managers. As 
stated previously, the loading of x-ray contrast agents is the same as the loading of 
all other medicines put together (§2.2). Given that the patients do not regard the use 
of urine bags as particularly onerous, it would be wise to further investigate the use 
of urine bags for the elimination of medicine residues. If this is successful, the effect 
could be expanded by tackling this across the entire 'flow'.
Experiences with effect measurements within this research are also very valuable 
for water managers. They provide an insight into measuring effects on the basis 
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of a mass balance and the complications that play a role in this context. The most 
important recommendation is first to create a mass balance in the baseline scenario, 
prior to this mass balance being used for the purposes of effect measurements. Other 
recommendations are included in a note that can be requested from Water Authority 
Groot Salland. 
4.3.3 Follow-up research
Any follow-up research could deliver far-reaching insights into the practical usage of 
urine bags. Research could focus on:
1. variations in the effectiveness of urine bags between specific sub-groups of 
patients;
2. the successful use of urine bags in other, perhaps less intensive, settings;
3. the successful use of urine bags among medicine-users for a longer period.
The results of this type of follow-up research could lead to a second step being taken 
towards large-scale implementation of a source-focussed approach to reducing 
medicine residues in waste water.
1. Research among patients that are having a CT scan, when more 
background variables are measured.      ............................................. 
The current research was not able to distinguish any sub-groups as there was too 
little differentiation with respect to background variables and, to a large extent, 
unambiguous answers were given in response to questions and statements. 
No significant differences were therefore shown between willingness, use and 
intentions on one side, and gender or age on the other. Background variables, 
such as educational level, residential situation, household composition, health and 
illness details, could be correlated with user experiences and opinions regarding 
urine bag usage and the role of patients in the chain. More sub-groups could 
then be distinguished, as could specific target-groups for the further (customised) 
introduction of a urine bag strategy to prevent medicine residues ending up in 
waste water. 
2. Research into the willingness and use of urine bags among CT patients 
with another, less intensive, approach method to patients. ....... 
The approach method using research assistants within a hospital setting led to an 
unprecedented response rate that was much higher than the norm for this type of 
survey. This is certainly the case when you also consider that not all questionnaires 
were completed and returned but also that behavioural changes were actually 
made. The question is what degree of response, willingness and behavioural 
change would be achieved with a simple, paper instruction or a short explanation 
by the CT laboratory assistant. This is important in terms of an affordable, source-
focussed strategy that could be applied in practice on a much larger scale. 
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3. Research into urine bag user experiences and willingness among patient 
groups that would have to collect medicine residues via their urine for a longer, 
but limited, time-frame, e.g. during antibiotic treatment or chemotherapy. ... 
This research showed that almost 40% of patients did not rule out using urine 
bags for longer than 24 hours. Follow-up research could identify whether patients 
are also prepared to use the urine bags for a week or longer or if there are limits 
to the patients' willingness to cooperate in this context. A variant on this theme 
is follow-up research among medicine-users but with another (mobile) device, i.e. 
not a urine bag, being used to collect urine.
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Annex 1: Developments in water quality 
policy in Europe and the Netherlands 
Europe
The European Water framework directive (KRW) has been in force since the end of 
2000 (European Parliament, 2000). This directive aims to realise good chemical and 
ecological surface water quality by 2027 at the latest. The assessment is based on 
standards in the Priority Substance list that was added to the directive in 2008 and 
which originally contained 33 substances (European Parliament, 2008). The standards 
from this list were established in the Netherlands via the Environment and Planning Act 
- Monitoring Order (BKMW) in the Ministerial Regulation Monitoring Water Framework 
Directive (MR). This list, however, does not contain (standards for) medicines. In 2013, 
12 new substances were added to the list (European Parliament, 2013). The painkiller 
diclofenac and two hormones (pilhormone and natural oestrogen) were also proposed 
for the list but were not included. This was mainly due to the (very) low concept norms 
and the corresponding large-scale investments in additional purification steps at 
WWTP's. There will, however,  be comprehensive monitoring in the planning period 
2016-2021 as a result of inclusion on the European Watch list. 
This latest modified directive (Directive 2013/39/EU), also states that the European 
Commission will deliver a strategic approach for medicine contamination in water in 
2015 . In addition, the European Commission, in the context of this strategic approach 
and if appropriate, must draw up a proposal for a package of measures in 2017 
(European Parliament, 2013).
International cooperation between European countries on (waste) water quality 
is taking place via bodies such as the European federation EUREAU. Dutch water 
boards and drinking-water companies are represented within this federation via the 
Union and Water boards and Vewin. EUREAU has provided a collective standpoint on 
‘emerging substances’ and ‘source control’, whereby the focus lies on tackling the issue 
at the source. There is also collaboration on this problem at flow area level (Rhine14 
and Maas).
In December 2013, a report was published on behalf of the Executive Agency for Health 
and Consumers on the risk of medicine residues in the environment (BIO Intelligence 
Service, 2013). This elaborated on topics such as the routes, behaviour, risks for water-
based life and human health, influencing factors and possible solutions.
Annex 1
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The Netherlands
Medicine residues have been identified in Dutch waterways since the end of the 1990s. 
This was the provocation for an informative recommendation from the Dutch Health 
Council (Gezondheidsraad)15 in 2001, which demanded policy-related attention be paid 
to the presence and risk of medicine residues in water (Health Council, 2001). A working 
group '(animal) medicines in the environment' was then created, various exploratory 
(monitoring) studies took place and this topic was discussed at length in the House 
of Representatives (House of Representatives, 2007; House of Representatives, 2009; 
House of Representatives, 2012). 
During the revision of the Dutch list of specific contaminating and drinking-water 
related substances, under the Water framework directive 2012, three medicines and 
one x-ray contrast agent were placed on the 'Dutch Watch list'16 (Smits & Wuijts, 2012). 
These are being more thoroughly monitored and were evaluated at the beginning of 
2015. Findings regarding the risks for the Netherlands would seem to be quite positive 
(STOWA, 2015). Draft norms were created by the RIVM for these three medicines 
(Moermond, 2014). 
In June 2013, former Secretary of State Mansveld (Ministry of Infrastructure and 
Environment) sent a letter to the House of Representatives, on behalf of the Ministry 
of Health, Welfare and Sport (VWS) and Economic Affairs (EZ). This letter once again 
stresses the importance of reducing medicine residues and other micropollutants in 
surface water, and also proposes the following:
1. A source-focussed approach, targeting the first steps in the medicine chain.
2. Raising awareness and creating a sense of urgency in consultation with the 
parties concerned and, on this basis, exploring the options with respect to specific 
measures that focus on medicine residues and other micropollutants in the 
waste phase.
3. On the basis of this exploration, making agreements with the parties concerned 
about the period of time and location of additional measures for the purification 
of medicines.
4. Requesting coverage of these measures in international commissions for various 
catchment areas and within the European Union. 
In January 2014, a round-table meeting was held by the permanent commission 
for Infrastructure and Environment with participants from the medicines sector 
(pharmacists, pharmaceutical industry and hospitals), water chain parties (water 
boards, drinking-water sector and sewerage) and representatives from the fields 
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situation with respect to issues relating to public health' to the Dutch government and parliament (art. 21 Health Act) (Health 
Council, 2001)
16 Medicines carbamazepine, metformin and metoprolol and x-ray contrast agent amidotrizoic acid
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of science, research and innovation (House of Representatives, 2014a). The parties 
involved endorsed a chain-approach whereby a source-focussed method at the 
beginning of the chain is encouraged, supplemented with measures at the end of the 
chain. This approach will then be monitored by the government, and former Secretary 
of State Mansveld has now taken steps to stimulate a source-focussed approach within 
care organisations, pharmacies, the pharmaceutical industry and the water sector 
(House of Representatives, 2014b&c).
Former Secretary of State Mansveld has also take steps with regard to stimulating a 
source-focussed approach (House of Representatives, 2014b). 
• Care establishments: Development of the Environmental Thermometer, (a 
certifiable environmental management system that stimulates and guarantees 
sustainable operations) and the creation of the Green Deal (the importance of 
sustainable operations in care collectively implemented by the parties concerned) 
in collaboration with Economic Affairs (EZ), Public Health, Welfare and Sport (VWS), 
and Foreign Affairs (BZK).
• Pharmaceutical industry: Discussions held and follow-up talks planned with 
delegation from the pharmaceutical industry for exploring possible contribution 
to the social task (specifically solutions within hospitals). 
• Pharmacies: In consultation between the Minister for Public Health, Welfare and 
Sport and the Dutch society that represents pharmacists (Koninklijke Nederlandse 
Maatschappij ter bevordering der Pharmacie/KNMP), map out examples of 
agreements between municipalities, pharmacists and waste collection firms, and 
bring these to the attention of other parties. The aim is to remove barriers to 
pharmacies accepting unused or old medicines.
• Water sector: Conversations with water boards and drinking-water companies 
about developing an action plan for their contribution to the social task.
The Union of Water Boards and Association of drinking water companies in the 
Netherlands (Vewin) presented an action plan to the Secretary of State, on behalf of 
the water sector, in November 2014 (uvW and Vewin, 2014). This proposes a three-
pronged policy with a separate branch for communicating the results. The three 
branches are: 
1. Problem definition: ecological and human health effects
2. Source approach
3. Approach within the water chain.
The combination of existing and ongoing research, pilot projects, policy initiatives and 
other relevant informations from all chain parties also forms an important component. 
Annex 1
53
The approach to medicine residues in surface water was set out in the National Water 
Plan 2016-2021, which was presented in 2014. This approach contained the same 
principles as outlined above.
Given the ambitions and complexity of the water quality policy, Minister Schultz 
van Haegen requested advice on this topic from the Advisory Commission Water 
(AcW). This commission, in the first part of its recommendation, indicated that it was 
concerned about developments in water quality and the speed at which measured 
were being taken (Advisory Commission Water, 2015). According to the AcW, the 
Netherlands is lagging behind in its approach to new substances in the Rhine 
catchment area. Various participants have been working on the problem definition 
for fifteen years but there is a lack of coordination. The chain parties are scared to 
take responsibility due to the corresponding costs. The implementation of measures 
and formulation of policy is therefore delayed. In addition, the various frameworks 
(water quality, monitoring, acceptance of substances, etc) must be harmonised more 
effectively. There is also still a substantial lack of expertise on the effects of substances 
on man and the environment and the corresponding measures. It takes a great deal 
of time to acquire this knowledge, but on the basis of the precautionary principle, this 
does not necessarily have to be a barrier to (considering) implementing measures. 
According to the AcW, it is necessary to first create agreement between all parties 
about urgency and also collectively recognise the problems. This requires a national 
approach with greater direction. Subsequently, the Minister, in a letter to the House 
of Representatives, indicated that he would provide direction and that the definitive 
advice from the AcW (end 2015) would be used to further substantiate and execute the 
water quality policy (House of Representatives, 2015b) 
An interdepartmental working group, set up by and under the directorship of 
the Ministry of Infrastructure and Environment (I&M) is currently working on the 
development of an action plan for medicine residues in the chain. This is expected to be 
presented to the Minister at the beginning of 2016 (C. Blom, personal communication, 
17 August 2015).
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Annex 2: Possible intervention points for 
measures in the medication chain according 
to RIVM 
According to the RIVM, the possible measures for the various points in the medicine 
chain are as follows:
A: Development of medicines with more favourable environmental properties and 
making the environmental data for medicine more readily available. This could impact 
upon raising the awareness of citizens and thus increase social demand thereafter
Annex 2
Figure 1:
Medicine chain. How do medicines end up in the environment? (RIVM, 2015). 
A. Development and production; 
B. Access to the market; 
C. Purchasing and sales by pharmacies; 
D. Prescription and use; 
E. Disposal with household waste; 
F. Disposal via sewerage system; 
G. Collection of unused medicines; 
H. Collection of household waste; 
I. Treatment of sewerage water; 
J. Dump for household waste; 
K. Incineration of household waste and   
 sludge; 
L. Sewerage sludge used in agriculture (not  
 in NL); 
M. Treated waste water is discharged into   
 surface water; 
N. Small chemical waste is incinerated; 
O. Drinking water companies supply water.
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B: Including environmental impact in decisions with regard to admitting medicines 
to the market and/or allowing them to be sold freely by drug stores/supermarkets. 
Information about the environment included in the instruction leaflet or as an 
environmental seal of approval on the packaging. 
C: Include consequences of medicine usage in the training of pharmacists and doctors. 
Oblige insurers to include not only price, but also environmental aspects when making 
decisions regarding the medicine reimbursement system. 
D: Patients could modify lifestyle or diet in some cases. Environmental aspects included 
when developing guidelines for doctors. Optimisation of quantities of medicines per 
patient. Information about environmental aspects and method of returning excess 
medicines provided to patients by pharmacies. 
E: Encourage patients to return medicines that have passed use-by dates to the 
pharmacy or collection point for small chemical waste. Develop laws with respect to 
the collection of waste that contains medicines. 
F: Patients could use urine bags or special toilets after medicine usage in order to limit 
known environmental effects.
G: Remove the financial barriers that prevent pharmacies accepting returned 
medicines. Conduct research into the extent to which it is possible to re-issue unused 
medicines. Ensure a good, accessible collection system for small chemical waste by 
municipalities. 
I: WWTP’s could add in treatment steps and develop more advanced purification 
methods. Reduce leaks and overflows via better management and design of sewerage 
system. Decentralised purification of hospital waste water. 
O: Drinking water companies could invest in methods for purifying drinking water 
(RIVM, 2015).
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Annex 3: Work instruction for Deventer 
Hospital research assistants for Grip
1. Optional: leave your bag/jacket in the locker in the hall (behind taxi point)
2. You can hang your jacket up in the changing room in the department, behind the 
large sliding door. Do not leave any valuables unattended. This room contains a 
stock of bags, empty forms, pens, clipboards, etc; these must be left here. Please 
shut the sliding door at the end of the day (rotating knob on inside) and then leave 
by the by the back exit.
3. You may take your own telephone with you and use it in the department. If 
you must call Inge, Yolanda or a colleague, you can do this free of charge at the 
reception in the hall.
4. Put your personnel pass and name badge on.
5. Walk round the back (via the door with a card reader) to the back of the desk (45); 
the second set of desks is the Radiology Planning section. Ask for the daily plan. All 
of the people who have been administered contrast agent (not a drink or anything 
else) will be approached.
6. Take a stock of everything with you to the CT/MRI waiting room or the seating area 
in the PET-CT corridor. Make sure you have two types of bag: female (green/pink) 
and male (blue).
7. Take a seat on the bench to the right (opposite the doors to the CT changing 
cubicles) or the seat by the PET-CT. You can then see who is going in and out. Only 
approach people who are on their way out. Please use the script for this purpose.
8. Who you can approach: polyclinic patients for a CT or PET-CT scan.
9. Who you cannot approach: clinical patients, patients who have not had contrast 
agent, small children (cross these off on your plan).
10. After the survey, people are asked to remain in the waiting room for around 15 
minutes and drink a glass of water (to see if there is any reaction to the injected 
contrast agent). If people have been before, and know they are not allergic to the 
substance, they will leave immediately. Try to speak to them too, and follow the 
script.
11. Patients that are on the plan twice, will be undergoing multiple examinations in 
one go but they will only come out once. You can write any notes on the plan, e.g. 
people who did not turn up, who you missed or who did not have any contrast 
agent, or any other details.
12. Let people fill out the short questionnaire themselves and check they they have 
completed it in full. If they ask for help, you may help but it is better if they do it 
themselves. People may fill out their phone number if they do not wish to give 
their email address (or the other way around). This will be used to call them at 
a later date if they have not returned the longer questionnaire or it is returned 
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incomplete. It will not be used for any other purpose. NB: You do not need to fill 
in the amount of contrast agent!
13. On the plan, note the number of the questionnaire after the name of the patient 
to which you gave it. 
14. If people would rather not take a bag, please ask them to fill in the short 
questionnaire. Note the reason why the patient did not want to cooperate on the 
short questionnaire. Add the long questionnaire to the short questionnaire so that 
the numbering is correct.
15. If patients do not wish to complete the short questionnaire, please complete a 
short questionnaire yourself (date, scan, gender). Write on the questionnaire 
'COMPLETED BY VOLUNTEER'. Note the reason why the patient did not want to 
cooperate on the short questionnaire. If patients do not give a reason, just note 
'reason unknown'. 
16. It is just as valuable, for the study, if people who do not wish to cooperate, fill in the 
long questionnaire. Always try to ask people to complete the long questionnaire 
even if they do not want to cooperate in the study (do not complete with the 
patient!). Give them the long questionnaire plus the reply-envelope and also the 
coffee voucher ('perhaps you could fill it in while enjoying a cup of coffee'). NB: 
Make sure you do not offer this as a 'way out'. In other words, don't say to someone 
who looks like they may take part 'oh you could just fill in the questionnaire'. You 
may only ask this if you are certain that the patient does not want to take part! 
17. If someone is unsure whether they wish to take part, suggest that they go home 
and have a think about it and, if they decide to take part, fill in and return the 
questionnaire (then we know why they did not want to take part). 
18. If patients indicate that they have participated already, because they already had 
a CT scan, they do not need to take part again. If a patient is unhappy with this 
approach, please given them urine bags anyway. These patients should not be 
given a number. Note on the plan that the patient had already participated and 
was issued with urine bags.
19. If you are unexpectedly unable to approach patients, for whatever reason, write 
on the plan 'not approached' and the reason why.
20. Place the long questionnaire (that has the same number as the short questionnaire) 
in the bag. Always keep the short questionnaire yourself. Check once again that 
the number on the completed short questionnaire is the same as the number on 
the long questionnaire that you place in the bag. 
21. Show the patient the things that are in the bag and explain briefly what they are 
for. Now, you can check that you have the right urine bags (male/female). There 
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are 7 urine bags in the bag. The disposable bags could be used if the person 
concerned is out of the house or not near a waste bin.
22. If anyone indicates that they need to go to the toilet immediately, point them to 
the disabled toilet (right, around the corner in the hallway). Please place the urine 
bag in the bin that is in the toilet cubicle. PET-CT: there is a toilet opposite the 
waiting room where patients sit.
23. If there is a programme on at PET-CT, you will be given 2 lists (at the bottom of the 
page, you will see CT 1 - this is the large waiting room - or N8 - that is the small 
waiting room). If you have time and there are a few patients one after the other, 
you could pop over to the other waiting room. If anyone is hard of hearing, you 
could sit with them on the bench at the front.
24. At the end of the day, hand the plan and the completed short questionnaires to 
the Radiology office; they will collate the lists (and plans) and send them in at the 
end of the week. The rest of the items must be put back in the changing room and 
close the door. 
25. Plan you own break on the basis of the plan. You can take your break in the coffee 
room in the radiology department or in the personnel canteen on the 1st floor. 
You can use the vending machines there that provide free coffee and tea. 
26. Sometimes there is a great deal of time between the last few patients, you do 
not need to wait for 1 or 2 patients, if there is more than an hour in between 
appointments.
27. If you run out of bags, please inform the department: Inge Vreeswijk, head of 
Radiology department or Yolanda.
28. Keep to the script as far as possible and the text that is given on the 'question 
and answer' form. If you do not know the answer, just say you don't know. Keep 
explanations brief and try not to go into too much detail about environmental 
aspects as this could impact too much on the research. 
29. Be aware that most of the people will be quite stressed when waiting so do your 
work quietly and adapt the level of your voice. Maintain the sense of calm in the 
waiting room as much as you can.
30. The research is not anonymous (because you are taking telephone numbers and/
or email addresses) but the details will be treated in confidence.
31. In the waiting room, an information film from the Water board will be shown and 
the laboratory assistants will also tell the patients about your presence. For more 
information, you can refer people to Water Authority Groot Salland's website: wgs.
nl./grip or provide their phone number: 038 455 74 34.
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Annex 4: Cronbach’s alpha
The reliability of a scale that contains various items can be analysed using Cronbach's 
alpha. This is a measure of the scale's internal consistency. Cronbach’s alpha is a 
method of establishing whether multiple items together form a scale (underlying 
structure). This is checked on the basis of the correlation between the various items. 
Values between .70 and .90 demonstrate high internal consistency. 
The concept of 'thinking in environmental solutions' encompasses the following 
statements:
Annex 4
Corrected Item-
Total Correlation
Cronbach’s Alpha 0.562; 
N of items 4
Cronbach's Alpha 
if Item Deleted
In the future, I will use a urine bag in 
order to make an environmental 
contribution.
As a patient, I would like to do my bit 
to resolve the issue of medicine 
residues in our water.
Hospitals should issue urine bags as 
standard, in order to collect medicine 
residues..
Collecting urine in a urine bag instead 
of the urine ending up in the sewer-
age system, and thus in the surface 
water, is better for the environment.
,296
,448
,378
,435
,598
,400
,481
,407
61
The reliability of a scale that contains various items can be analysed using Cronbach's 
alpha. This is a measure of the scale's internal consistency. Cronbach’s alpha is a 
method of establishing whether multiple items together form a scale (underlying 
structure). This is checked on the basis of the correlation between the various items. 
Values between .70 and .90 demonstrate high internal consistency. 
The concept of 'thinking in environmental solutions' encompasses the following 
statements:
Alpha Cronbach’s scores 0.614.on the 'environmental solutions' scale. This is 
insufficiently high to construct a 'thinking in alternatives' scale.
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Corrected Item-
Total Correlation
Cronbach’s Alpha 0.614; 
N of items 4
Cronbach's Alpha 
if Item Deleted
It would be better to adapt sewerage 
treatment systems than ask 
medicine-users to collect their urine.
Patients should not be trouble about 
environmental problems resulting 
from their medicine usage.
Medicine users are asked to use 
urine bags too frequently.
It would be better to adapt medicines 
than ask medicine-users to collect 
their urine.
,454
,309
,395
,432
,503
,613
,543
,515
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Annex 5: Map of sewerage catchment area 
Deventer
Annex 5
10 cm
DEVENTER HOSPITAL
Sewerage area (dirty water sewer, centrally drained)
Legenda
Sewerage area (Improved separation system, rainwater)
Sewerage area (pressure sewerage system)
Sewerage area (mixed system)
Sewerage area (separated system)
Sewerage area (improved separation system)
WWTP DEVENTER
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